Understanding Advanced Prostate Cancer

/Understanding Advanced Prostate Cancer

Strolling Towards Death

Strolling Towards Death Bob H. I’m dying.  Yes, yes, we’re all dying, from the moment of birth, blah, blah, blah.  But me, a little more so.  My cancer is back. I’m not sick.  I have an illness, if that’s what prostate cancer is. Or a disease.  Or a condition.  I’ve periodically read a lot.  Swirls [...]

By |2019-06-05T16:53:53-04:00June 11th, 2019|Understanding Advanced Prostate Cancer|0 Comments

When Doctors Cry “TMI!”

When Doctors Cry “TMI!” Robert Hanlon Recent stories have highlighted genetic testing that may predict an 87% likelihood of getting a certain rare type of cancer.  These reports provide a tantalizing, if scary, hope of informed decision-making about medical treatments.  But don’t be fooled.  To date, only a very small percentage of the population and [...]

By |2019-06-05T16:55:16-04:00May 28th, 2019|Understanding Advanced Prostate Cancer|0 Comments

Kegel Smegal

Steven Lavender reference https://theptpractice.nyc By now many of you would have heard the word Kegel.  Arnold Kegel was an American gynecologist who developed exercises to strengthen “relaxed genitals” in females.  The exercises have been well studied and are now taught to both men and women as the first line of defense against incontinence both urinary [...]

By |2019-06-05T16:56:03-04:00April 16th, 2019|Understanding Advanced Prostate Cancer|0 Comments

Malecare – 20 Year Celebration in NYC

Celebrate 20 years of Malecare Prostate Cancer Support Groups., at a special two hour discussion with three of NYC"s top cancer doctors. Your questions will be welcome! Dr. Kelly Cassano, Senior Associate Dean for Clinical Affairs, Chief of Ambulatory Care at Mount Sinai Downtown William K. Oh, MD, Medical Oncologist and Robert Stewart, MD, Radiation [...]

By |2018-09-20T11:58:32-04:00September 20th, 2018|Understanding Advanced Prostate Cancer|0 Comments

XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces developing metastases or death

Non-metastatic Castrate Resistant prostate cancer patients take note.  The Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) showed that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 percent compared to ADT alone.  It will be a [...]